Compare iShares 3 7 Year Treasury Bond ETF (IEI) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 3 7 Year Treasury Bond ETF vs Regeneron Pharmaceuticals Inc — how do they compare? iShares 3 7 Year Treasury Bond ETF trades at $113.42 (market cap $16.72B), while Regeneron Pharmaceuticals Inc trades at $744.68 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 4.6× iShares 3 7 Year Treasury Bond ETF's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while iShares 3 7 Year Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares 3 7 Year Treasury Bond ETF for 43 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| IEI | REGN | |
|---|---|---|
Market Cap | $16.72B | $76.14B |
Volume | 3,963,319 | 500,239 |
Sector | Fixed Income | Health |
52-Week High | $120.72 | $852.03 |
52-Week Low | $113.17 | $557.73 |
Typical Hold Time | 43 Days | 107 Days |
Enterprise Value | — | $70.85B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEI trades at $113.41, showing minimal daily movement with a 0.03% gain. Technical indicators signal a bearish trend with moving averages and ADX pointing downward, though oscillators remain neutral. Recent dividend payments of $0.37-0.38 per share provide income stability. The stock faces headwinds from broader bond market volatility as Treasury yields reach multi-decade highs, impacting fixed-income related equities.
The outlook remains cautious amid persistent bond market pressures. While dividend payments offer some support, the bearish technical setup and elevated Treasury yields create near-term challenges. Investment opportunity exists for income-focused investors, but requires careful monitoring of interest rate developments and bond market stability.
Regeneron Pharmaceuticals (REGN) trades at $739.28, down 0.38% on the day, with a bearish technical signal and neutral oscillators. The company shows strong fundamentals with a P/E of 18.3, net income margin of 27.86%, and consistent earnings beats in recent quarters. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, including a $1 billion upfront payment, reinforcing its pipeline strength and long-term growth prospects.
The outlook remains positive driven by robust profitability, strategic collaborations, and a bullish analyst consensus with a $849.84 price target. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. Institutional sentiment is strong with no sell ratings, supporting a favorable risk-reward profile for investors seeking exposure to biopharmaceutical innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares 3 7 Year Treasury Bond ETF
IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
